How Much Can Nuvation Bio (NUVB) Make From Ibtrozi Sales? [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
The stock carries a Strong Buy rating with an average price target of $11.93, which indicates more than 160% upside. How Much Can Nuvation Bio Inc (NUVB) Make From Ibtrozi Sales? Photographee.eu/Shutterstock.com On April 8, Truist Securities restated its Buy rating on Nuvation Bio Inc (NYSE:NUVB) with a price target of $12. This action followed the firm's meetings with Nuvation Bio's management. The meeting covered a variety of topics, including the launch of the company's Ibtrozi drug and its safusidenib drug candidate. Ibtrozi is an FDA-approved treatment for lung cancer, while safusidenib is being developed to treat gliomas and other solid tumors. Truist noted that the Ibtrozi launch has had a bright start, pointing out potential to add around 200 points per quarter in the short-term. Moreover, the firm noted potential to expand the drug's market penetration with additional testing. Regarding safusidenib, Truist said it remained constructive on the candidate's long-term p
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 [TheStreet.com]TheStreet.com
- Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026PR Newswire
- Nuvation Bio's Ibtrozi Gains Frontline Momentum Ahead of Key Q1 Print, Wedbush Says [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.MarketBeat
- Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks [Yahoo! Finance]Yahoo! Finance
NUVB
Earnings
- 3/2/26 - In-Line
NUVB
Sec Filings
- 4/21/26 - Form DEFA14A
- 4/17/26 - Form 144
- 4/17/26 - Form 144
- NUVB's page on the SEC website